Richard de Boer

Summary

Affiliation: Western Hospital
Country: Australia

Publications

  1. pmc Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
    Richard H de Boer
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan St, 2nd Floor, Parkville, Melbourne, VIC 3050, Australia
    Breast Cancer Res Treat 135:241-52. 2012
  2. doi request reprint An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
    R de Boer
    Department of Medical Oncology, Western Hospital, Melbourne, Australia
    Ann Oncol 20:486-91. 2009
  3. doi request reprint Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies
    Richard de Boer
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan St, Parkville, 3050, Australia
    Med Oncol 28:1210-7. 2011
  4. ncbi request reprint Undertreatment of elderly patients with non-small-cell lung cancer
    Raymond Ng
    Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia
    Clin Lung Cancer 7:168-74. 2005
  5. ncbi request reprint Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer
    Ross R Jennens
    Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    Chest 126:1985-93. 2004

Detail Information

Publications5

  1. pmc Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
    Richard H de Boer
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan St, 2nd Floor, Parkville, Melbourne, VIC 3050, Australia
    Breast Cancer Res Treat 135:241-52. 2012
    ..The objective response rate of 56 % suggests a potential benefit of motesanib in combination with taxane-based chemotherapy...
  2. doi request reprint An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer
    R de Boer
    Department of Medical Oncology, Western Hospital, Melbourne, Australia
    Ann Oncol 20:486-91. 2009
    ..The safety and tolerability of vandetanib plus pemetrexed was assessed in patients with advanced non-small-cell lung cancer (NSCLC)...
  3. doi request reprint Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies
    Richard de Boer
    Department of Medical Oncology, Royal Melbourne Hospital, Grattan St, Parkville, 3050, Australia
    Med Oncol 28:1210-7. 2011
    ..16 (-1.8 to 1.3), 0.21 (-1.5 to 3.4), and 0.76 (-1.0 to 2.9) g/dl in cohorts A1, A2, and A3, respectively. AMG 114 appeared to be well tolerated, but the study was halted, in part because of modest efficacy...
  4. ncbi request reprint Undertreatment of elderly patients with non-small-cell lung cancer
    Raymond Ng
    Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia
    Clin Lung Cancer 7:168-74. 2005
    ....
  5. ncbi request reprint Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer
    Ross R Jennens
    Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia
    Chest 126:1985-93. 2004
    ..To quantify clinician knowledge and bias regarding the role of chemotherapy for stage IV non-small cell lung cancer (NSCLC)...